Skip to Content
  • Previous Rank
    20
  • Revenues ($M)
    100,887
  • Revenue Percent Change
    -3.6%
  • Profits ($M)
    2,008
  • Profits Percent Change
    8.8%
  • Market Value (as of March 31, 2015)
    63,237

Express Scripts, a full service pharmacy benefits manager, has been benefitting from industry consolidation that has cut costs and boosted their bargaining strength as pharmaceutical companies release high-priced treatments for hepatitis C and high cholesterol. Express Scripts led the wave of consolidation when it bought Medco Health Solutions for almost $30 billion in 2012. The deal doubled its revenues and positioned the company as the No. 1 pharmacy benefits manager. The St. Louis, Mo.-based company has also benefitted from more insured patients, a result of the Affordable Care Act. Express Scripts has used its industry-leading position to wring out savings on high-cost specialty drugs for its users, which will become more necessary as more innovative treatments come on the market. Specialty pharmacy is expect to grow by about 20% over the next few years and customers will rely on PBM’s to help them better manage this spend.

Company Info

CEO
Timothy C. Wentworth
Industry
Health Care: Pharmacy and Other Services
Sector
Health Care
HQ Location
St. Louis, MO
Websitehttp://www.express-scripts.com
Years on List16
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)100,887-3.6%
Profits ($M)2,0088.8%
Total Stockholder Equity20,054-
Employees29,500-
Market Value (as of March 31, 2015)63,237-

Profit Ratios

Profit as % of Revenues2%
Profits as % of Assets3.7%
Profits as % of Stockholder Equity10%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)2.64
EPS % Change (from 2013)17.3%
EPS % Change (5 year annual rate)11.2%
EPS % Change (10 year annual rate)19.4%

Total Return

Total Return to Investors (2014)20.5%
Total Return to Investors (5 year, annualized)14.4%
Total Return to Investors (10 year, annualized)24.4%